White label ELPA - ClinicalTrials.eu

Study on Ketamine and Midazolam for Adults with Depression and Alcohol Use Disorder

Recruiting

1 1 1
Investigated Drugs:
- Midazolam Hydrochloride
- Ketamine
Study on Valacyclovir for Preventing and Treating Cytomegalovirus (CMV) in Pregnant Women

Recruiting

2 1 1 1
Investigated Diseases:
- Cytomegalovirus infection
Investigated Drugs:
- Valaciclovir
Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer stage IV
Investigated Drugs:
Study on Simvastatin for Treating Primary Sclerosing Cholangitis in Patients

Recruiting

2 1 1
Investigated Diseases:
- Cholangitis sclerosing
Investigated Drugs:
- Simvastatin
Study on the Effectiveness and Safety of Tinengotinib for Patients with Cholangiocarcinoma Resistant to Chemotherapy and FGFR Inhibitors

Recruiting

3 1 1 1
Investigated Diseases:
- Cholangiocarcinoma
Investigated Drugs:
+2
Study on the Effectiveness and Safety of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

Recruiting

3 1 1 1
Investigated Diseases:
- Spinal muscular atrophy
Investigated Drugs:
- Risdiplam
Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Recruiting

1 1 1 1
Investigated Diseases:
Investigated Drugs:
- Temsirolimus
- Crizotinib
+3
Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis Who Have Not Responded Well to Previous Biologic Treatments

Recruiting

3 1
Investigated Drugs:
- Risankizumab
+4
Study of BGB-11417 and Azacitidine for Patients with Myeloid Malignancies (AML, MDS, MDS/MPN)

Recruiting

1 1 1 1
Investigated Drugs:
Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Recruiting

1 1 1 1
Investigated Diseases:
- Neoplasm malignant
Investigated Drugs:
- Anti-(Fc Fragment Of Igg Receptor Iib) Monoclonal Antibody Bi-1206
- Pembrolizumab

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies